Company intelligence / Profile preview

Sunbird Bio

Cambridge, Massachusetts, United Statessunbirdbio.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Sunbird Bio is developing blood-based diagnostic tests that can directly detect and differentiate specific proteins that aggregate in the brain and signal the presence of neurological diseases. The company plans to initiate additional clinical studies by early 2025.

Therapeutic areas: OncologyNeurology
Modalities: Protein-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Eli Lilly and Company

Beyond the preview

Go deeper on Sunbird Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunbird Bio.

Explore the full profile